Biocon Limited has informed the Exchange regarding a press release dated Jun 24, 2026, titled "Biocon Reinforces Commitment to Diabetes Care in Malaysia as Partner Duopharma Biotech Secures Insulin Tenders".
Biocon Limited Press Release Jun 24 2026
Filed with NSE · · 4 pages · English
Release
Earlier from Biocon
- Press Release May 07 2026
- Press Release Apr 21 2026
- Biocon Receives Health Canada Approval of Bosaya™ (Denosumab) and Vevzuo™ (Denosumab), Biosimilars to Prolia® and Xgeva®
- Press Release Apr 07 2026
- Shreehas Tambe Appointed CEO and Managing Director of Biocon Limited, Effective April 1, 2026
Later from Biocon
- Biocon Limited Press Release Jul 09 2026
- Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)
- Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili, a Biosimilar to Eylea
- Biocon Limited Press Release Aug 03 2026
- Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg
Follow Biocon into a list and get an email when it puts out news.
Follow Biocon